We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: measurable residual disease
MedXY News
EnglishTag

measurable residual disease

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Pre-Transplant KMT2A-PTD Measurable Residual Disease as a Prognostic Biomarker in Acute Myeloid Leukemia Allogeneic Stem Cell Transplantation
Hematology-Oncologymeasurable residual diseaseacute myeloid leukemia

Pre-Transplant KMT2A-PTD Measurable Residual Disease as a Prognostic Biomarker in Acute Myeloid Leukemia Allogeneic Stem Cell Transplantation

By MedXY|Sep 11, 2026

The presence of measurable residual KMT2A partial tandem duplication before allogeneic stem cell transplantation in AML significantly predicts poorer survival outcomes, highlighting its potential as a critical MRD biomarker for risk stratif

Real-World Impact of Post-Treatment Circulating Tumor DNA Monitoring in Large B-Cell Lymphoma Using an Immunoglobulin-Based Assay
Hematology-Oncology
measurable residual disease
Large B-Cell Lymphoma

Real-World Impact of Post-Treatment Circulating Tumor DNA Monitoring in Large B-Cell Lymphoma Using an Immunoglobulin-Based Assay

By MedXY|Aug 25, 2026

This study demonstrates that detection of circulating tumor DNA (ctDNA) after treatment in large B-cell lymphoma predicts progression-free survival, highlighting the clinical utility of a rapid immunoglobulin rearrangement-targeted assay fo

Integrating Genetics and Measurable Residual Disease to Optimize Therapy in Philadelphia Chromosome-Negative Adult ALL
Hematology-Oncologymeasurable residual diseaseallogeneic hematopoietic stem cell transplant

Integrating Genetics and Measurable Residual Disease to Optimize Therapy in Philadelphia Chromosome-Negative Adult ALL

By MedXY|Aug 25, 2026

Combining genetic risk stratification with measurable residual disease enables precise treatment allocation in adult Philadelphia chromosome-negative acute lymphoblastic leukemia, improving survival outcomes and guiding the use of allogenei

Measurable Residual Disease as a Prognostic Biomarker in Frontline Azacitidine and Venetoclax-Treated AML: Insights from the French VENAURA Registry
Hematology-Oncologyacute myeloid leukemiaazacitidine

Measurable Residual Disease as a Prognostic Biomarker in Frontline Azacitidine and Venetoclax-Treated AML: Insights from the French VENAURA Registry

By MedXY|Jul 20, 2026

In AML patients receiving frontline azacitidine and venetoclax, achieving measurable residual disease negativity strongly predicts longer survival and lower relapse rates, overriding baseline risk factors, as shown in the French VENAURA reg

Next-Generation Sequencing MRD Detection Predicts Outcomes in AML Patients Undergoing Allogeneic Stem Cell Transplantation
Hematology-Oncologyacute myeloid leukemiaallogeneic stem cell transplantation

Next-Generation Sequencing MRD Detection Predicts Outcomes in AML Patients Undergoing Allogeneic Stem Cell Transplantation

By MedXY|May 30, 2026

A low-cost NGS-based MRD test detected hidden AML cells before transplant and strongly predicted worse survival after allogeneic stem cell transplantation.

MRD Does Not Consistently Predict PFS Across Modern CLL Trials: Why Surrogacy Depends on Therapy, Duration, and Sample Source
Hematology-OncologyCLLmeasurable residual disease

MRD Does Not Consistently Predict PFS Across Modern CLL Trials: Why Surrogacy Depends on Therapy, Duration, and Sample Source

By MedXY|May 4, 2026

A large meta-analysis shows MRD strongly predicts outcomes for individual patients with CLL, but is an inconsistent trial-level surrogate for progression-free survival, particularly with BTK inhibitor and venetoclax-based regimens.

Genomic Fusion Breakpoints: A Breakthrough in Pediatric ALL MRD Monitoring
Hematology-Oncologygenomic fusion breakpointsmeasurable residual disease

Genomic Fusion Breakpoints: A Breakthrough in Pediatric ALL MRD Monitoring

By MedXY|Apr 24, 2026

A novel genomic fusion breakpoint (GFB)-based MRD monitoring approach demonstrates superior sensitivity and specificity in pediatric ALL, addressing limitations of current IG/TCR-based methods, particularly in ETV6::RUNX1- and MEF2D-rearran

Hematology-Oncologyclinical trialsmeasurable residual disease

MRD-Guided Intensification: A Tailored Approach to First-Line Chronic Lymphocytic Leukaemia Treatment

By MedXY|Dec 19, 2025

The HOVON 158/NEXT STEP phase 2 trial demonstrates that a measurable residual disease (MRD)-guided intensification strategy using ibrutinib and obinutuzumab significantly deepens remissions in first-line CLL patients who do not achieve deep

AlloHSCT in Adult Ph– ALL Treated with Pediatric-Inspired GIMEMA LAL1913: MRD Status at Transplant Drives Long-Term Outcomes
Hematology-OncologyAcute Lymphoblastic Leukemiaallogeneic stem cell transplantation

AlloHSCT in Adult Ph– ALL Treated with Pediatric-Inspired GIMEMA LAL1913: MRD Status at Transplant Drives Long-Term Outcomes

By MedXY|Nov 17, 2025

Campus ALL real-world data show that pre-transplant MRD negativity after the pediatric-inspired GIMEMA LAL1913 protocol predicts substantially better 3‑year OS and DFS after alloHSCT; MRD-positive patients and those in CR2 fare markedly wor

Tailoring Transplant Conditioning and Maintenance Therapy in FLT3-ITD AML: Insights on NPM1 Mutations and Measurable Residual Disease
Hematology-Oncologyacute myeloid leukemiaFLT3-ITD

Tailoring Transplant Conditioning and Maintenance Therapy in FLT3-ITD AML: Insights on NPM1 Mutations and Measurable Residual Disease

By MedXY|Nov 4, 2025

Posttransplant gilteritinib greatly benefits FLT3-ITD AML patients with NPM1 comutations, while myeloablative conditioning offers limited advantages over reduced-intensity conditioning in eradicating measurable residual disease.

Molecular Monitoring of MRD in Pediatric AML with KMT2A::MLLT10: Prognostic Insights and Clinical Impact
Hematology-OncologyKMT2A::MLLT10measurable residual disease

Molecular Monitoring of MRD in Pediatric AML with KMT2A::MLLT10: Prognostic Insights and Clinical Impact

By MedXY|Oct 14, 2025

MRD monitoring by RT-qPCR in pediatric AML with KMT2A::MLLT10 fusion identifies patients at high risk despite morphologic remission, informing prognosis and guiding therapy.

Advancing Chronic Lymphocytic Leukemia Management: The Impact of Measurable Residual Disease-Guided Ibrutinib-Venetoclax Therapy
Clinical Updates慢性淋巴细胞白血病，免疫球蛋白水平，单克隆 B 细胞淋巴细胞增多症，癌症易感性Ibrutinib

Advancing Chronic Lymphocytic Leukemia Management: The Impact of Measurable Residual Disease-Guided Ibrutinib-Venetoclax Therapy

By MedXY|Oct 9, 2025

Phase 3 trial data demonstrate that ibrutinib-venetoclax therapy achieves superior undetectable measurable residual disease rates and significantly prolonged progression-free survival compared with ibrutinib alone or FCR in chronic lymphocy

MRD-Guided Consolidation Therapy in Newly Diagnosed Multiple Myeloma: Insights from the MIDAS Phase 3 Trial
Clinical Updatesautologous stem-cell transplantationmeasurable residual disease

MRD-Guided Consolidation Therapy in Newly Diagnosed Multiple Myeloma: Insights from the MIDAS Phase 3 Trial

By MedXY|Sep 30, 2025

MRD-guided consolidation strategies in transplant-eligible multiple myeloma patients did not significantly improve deep remission rates over conventional approaches, questioning the clinical utility of MRD-adapted intensification.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities